WO2004076473A3 - Peptides interagissant avec le recepteur androgne - Google Patents

Peptides interagissant avec le recepteur androgne Download PDF

Info

Publication number
WO2004076473A3
WO2004076473A3 PCT/US2004/003774 US2004003774W WO2004076473A3 WO 2004076473 A3 WO2004076473 A3 WO 2004076473A3 US 2004003774 W US2004003774 W US 2004003774W WO 2004076473 A3 WO2004076473 A3 WO 2004076473A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
androgen receptor
ser
polypeptide sequences
receptor interacting
Prior art date
Application number
PCT/US2004/003774
Other languages
English (en)
Other versions
WO2004076473A2 (fr
Inventor
Benjamin M Buehrer
Thomas R Barnett
Original Assignee
Karobio Ab
Benjamin M Buehrer
Thomas R Barnett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karobio Ab, Benjamin M Buehrer, Thomas R Barnett filed Critical Karobio Ab
Publication of WO2004076473A2 publication Critical patent/WO2004076473A2/fr
Publication of WO2004076473A3 publication Critical patent/WO2004076473A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un polypeptide se liant au récepteur androgène, lequel polypeptide présente la séquence d'acides aminés Ar-X-X-Z-Ar ou Ser-β-Ar-X-?-?-Ar ou Ser-β-Ar-?-X-?-Ar ou Ser-X-Ar-X-X-?-Ar, dans laquelle Ar est un acide aminé aromatique ; X représente tout acide aminé et Z est un acide aminé hydrophobe (?) ou un acide aminé aromatique (Ar) ; β est un acide aminé basique et Δ est un acide aminé acide. Ladite invention concerne également des méthodes pour analyser la conformation de surface d'une protéine au moyen d'une ou de plusieurs des séquences polypeptidiques susmentionnées, des méthodes d'identification de modulateurs de la fonction protéique au moyen d'une ou de plusieurs des séquences polypeptidiques susmentionnées ainsi que des compositions pharmaceutiques contenant un excipient pharmacologiquement acceptable et une ou plusieurs des séquences polypeptidiques susmentionnées.
PCT/US2004/003774 2003-02-12 2004-02-10 Peptides interagissant avec le recepteur androgne WO2004076473A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44695503P 2003-02-12 2003-02-12
US60/446,955 2003-02-12

Publications (2)

Publication Number Publication Date
WO2004076473A2 WO2004076473A2 (fr) 2004-09-10
WO2004076473A3 true WO2004076473A3 (fr) 2005-03-17

Family

ID=32927463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/003774 WO2004076473A2 (fr) 2003-02-12 2004-02-10 Peptides interagissant avec le recepteur androgne

Country Status (1)

Country Link
WO (1) WO2004076473A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5030078B2 (ja) * 2006-02-15 2012-09-19 独立行政法人産業技術総合研究所 ボンベシン様ペプチド受容体を活性化するペプチド、およびその利用
EP1916257A1 (fr) * 2006-10-27 2008-04-30 Charite-Universitätsmedizin Berlin Mimotopes peptidiques de l'antigène GD2 pour la vaccination contre le cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942430A (en) * 1996-02-16 1999-08-24 Diversa Corporation Esterases
US20030045680A1 (en) * 2001-03-12 2003-03-06 Praecis Pharmaceuticals Inc. Peptidic modulators of the androgen receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942430A (en) * 1996-02-16 1999-08-24 Diversa Corporation Esterases
US20030045680A1 (en) * 2001-03-12 2003-03-06 Praecis Pharmaceuticals Inc. Peptidic modulators of the androgen receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DOHERTY ET AL.: "Structure-activity relationships of C-terminal endothelin hexapeptide antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 18, 3 September 1993 (1993-09-03), pages 2585 - 2594, XP002983399 *
HE ET AL.: "The FXXLF motif mediates androgen receptor-specific interactions with coregulators", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 12, 22 March 2002 (2002-03-22), pages 10226 - 10235, XP002983400 *

Also Published As

Publication number Publication date
WO2004076473A2 (fr) 2004-09-10

Similar Documents

Publication Publication Date Title
WO2001005950A3 (fr) Nouveaux procedes permettant la presentation de (poly)peptides/proteines sur des particules bacteriophages au moyen de liaisons disulfure
WO2005014049A3 (fr) Synthese et utilisation de nouveaux polymeres ramifies structuraux bien definis comme agents de conjugaison de peptides
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
WO2002059143A3 (fr) Peptides therapeutiques pour troubles de la demyelinisation
AU2002332390A1 (en) Proteins, druggable regions of proteins and target analysis for chemistry of therapeutics
EP1489424A4 (fr) Procede d'analyse d'un peptide visant a determiner une sequence d'acides amines c-terminaux
WO2004076473A3 (fr) Peptides interagissant avec le recepteur androgne
EP1577672A4 (fr) Procede d'analyse d'une sequence d'acide amine c terminal de peptide au moyen d'une spectrometrie de masse
WO2000058465A3 (fr) Analogues polypeptidiques de flint
WO2002000719A3 (fr) Nouveaux recepteurs
WO2002042458A3 (fr) Nouveaux recepteurs
AU2002232016A1 (en) Method of isolating charged compounds, especially peptides and proteins
EP1654280B8 (fr) Preparation de peptides somatostatine
WO2003099853A3 (fr) Procede d'amidation de peptide
WO2003093300A3 (fr) Peptides anti-microbiens et compositions
AU2002365084A1 (en) Method and reagent for the detection of proteins and peptides
WO2001087932A3 (fr) Sept protéines transmembranaires et polynucléotides les codant
WO2003004678A3 (fr) Nouveaux recepteurs
AU2003295435A1 (en) Biological carriers for the delivery of proteins or peptides
WO2004035733A3 (fr) Proteines hepsine/46 humaines isolees, molecules d'acide nucleique codant les proteines hepsine/46, et utilisations associees
AU2002361963A1 (en) Fusion proteins containing tlp peptides
WO2002031146A3 (fr) Recepteurs d'hormone nucleaire humaine isoles, molecules d'acides nucleiques codant des recepteurs d'hormone nucleaire humaine, et utilisations
WO2006047514A3 (fr) Analogues de daph et inhibition d'agregation de proteines
AU2003284493A8 (en) Method of analyzing C-terminal amino acid sequence of peptide
WO2002036633A3 (fr) Nouvelles proteines humaines 7tm et polynucleotides codant pour ces proteines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase